Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NeuroSearch. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NeuroSearch's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroSearch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare NeuroSearch's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare NeuroSearch's earnings growth to the Denmark market average as no estimate data is available.
Unable to compare NeuroSearch's revenue growth to the Denmark market average as no estimate data is available.
Unable to determine if NeuroSearch is high growth as no earnings estimate data is available.
Unable to determine if NeuroSearch is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NeuroSearch's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Allan Andersen, DVM, has been the Chief Executive Officer of Neurosearch A/S since December 1, 2013. He serves as the Chief Executive Officer and Director at NeuroSearch Sweden AB. Mr. Andersen also serves as the President of Freja Ejendomme A/S. He served as the Chief Executive Officer of AA Consult ApS. He served as the Chairman of Nordicom A/S. He served as the Chairman of Neurosearch A/S until December 1, 2013. He served as the Chairman of Udviklingsselskabet af 01.08. 1975 A/S since April 27, 2010. He served as the Deputy Chairman of Glunz & Jensen A/S. He has been a Director at Neurosearch A/S since 1990 and NeuroSearch AB since 1989. He has been a Director of Connectia A/S since 2006. He has been a Director of Schaumann Properties A/S since April 27, 2010. He serves as a Director of Freja ejendomme AS, PBI-Holding and Ringsted A/S. Mr. Andersen serves as a Director of Actics Ltd. He served as Director of Glunz & Jensen A/S from 1991 to 2005. Mr. Andersen served as a Director of Greater Europe Deep Value Fund Ltd, Greater Europe Deep Value Fund II Ltd., Greater Europe Fund Ltd, GEF SPV Ltd., AA Consult ApS and DVF SPV Ltd. He was Chairman at Park Street Nordicom A/S.
Insufficient data for Allan to compare compensation growth.
Allan's remuneration is lower than average for companies of similar size in Denmark.
CEO & Director
Vice President of Finance & Administration
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the NeuroSearch board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month individual insider trading information.
Should You Be Concerned About NeuroSearch A/S's (CPH:NEUR) Investors?
In this article, I will take a quick look at NeuroSearch A/S’s (CPH:NEUR) recent ownership structure – an unconventional investing subject, but an important one. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … CPSE:NEUR Ownership Summary July 19th 18
Breaking Down NeuroSearch A/S's (CPH:NEUR) Ownership Structure
But investors should also check whether hedge funds, mostly active investors with a short-term horizon, have a significant stake. … General Public Ownership The general public holds a substantial 74.90% stake in NEUR, making it a highly popular stock among retail investors. … An investor should be encouraged by the ownership of these institutions who are known to be experts in increasing efficiency, improving capital structure and opting for value-accretive policy decisions.Next Steps: While NEUR has a low level of institutional ownership, active hedge funds still hold a significant stake in the company.
NeuroSearch A/S does not have significant operations. Previously, the company was engaged in the research and development of drugs in the CNS segment. The company was founded in 1989 and is based in Hvidovre, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.